Calamos Advisors
BSX icon

Calamos Advisors’s Boston Scientific BSX Stock Holding History

Calamos Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$24.4M Sell
557,978
-119,136
-18% -$5.52M 0.07% 249
2026
Q2 		$28.9M Sell
677,114
-140,572
-17% -$7.63M 0.1% 209
2026
Q1 		$51.3M Sell
817,686
-53,971
-6% -$4.32M 0.18% 126
2025
Q4 		$83.1M Sell
871,657
-22,773
-3% -$2.23M 0.31% 66
2025
Q3 		$87.3M Sell
894,430
-105,849
-11% -$11M 0.32% 61
2025
Q2 		$107M Buy
1,000,279
+30,311
+3% +$3.07M 0.42% 42
2025
Q1 		$97.9M Sell
969,968
-57,089
-6% -$5.75M 0.43% 43
2024
Q4 		$91.7M Buy
1,027,057
+4,509
+0.4% +$397K 0.38% 48
2024
Q3 		$85.7M Sell
1,022,548
-9,364
-0.9% -$738K 0.37% 52
2024
Q2 		$79.5M Sell
1,031,912
-50,741
-5% -$3.71M 0.35% 51
2024
Q1 		$74.2M Sell
1,082,653
-37,911
-3% -$2.44M 0.35% 60
2023
Q4 		$64.8M Sell
1,120,564
-4,939
-0.4% -$264K 0.31% 76
2023
Q3 		$59.4M Buy
1,125,503
+2,499
+0.2% +$131K 0.31% 74
2023
Q2 		$60.7M Buy
1,123,004
+42,983
+4% +$2.24M 0.3% 73
2023
Q1 		$54M Sell
1,080,021
-128,640
-11% -$6.06M 0.26% 96
2022
Q4 		$55.9M Sell
1,208,661
-112,498
-9% -$4.87M 0.26% 95
2022
Q3 		$51.2M Sell
1,321,159
-3,026
-0.2% -$121K 0.23% 103
2022
Q2 		$49.4M Buy
1,324,185
+102,122
+8% +$4.16M 0.21% 113
2022
Q1 		$54.1M Buy
1,222,063
+105,492
+9% +$4.57M 0.2% 119
2021
Q4 		$47.4M Buy
1,116,571
+21,444
+2% +$901K 0.18% 135
2021
Q3 		$47.5M Sell
1,095,127
-55,354
-5% -$2.45M 0.21% 121
2021
Q2 		$49.2M Buy
1,150,481
+139,973
+14% +$5.89M 0.22% 109
2021
Q1 		$39.1M Buy
1,010,508
+280,323
+38% +$10.6M 0.21% 117
2020
Q4 		$26.2M Buy
730,185
+19,257
+3% +$694K 0.15% 174
2020
Q3 		$27.2M Sell
710,928
-46,405
-6% -$1.79M 0.17% 147
2020
Q2 		$26.6M Sell
757,333
-389,033
-34% -$14M 0.19% 148
2020
Q1 		$37.4M Buy
1,146,366
+893,345
+353% +$34.9M 0.29% 95
2019
Q4 		$11.4M Sell
253,021
-7,913
-3% -$331K 0.06% 317
2019
Q3 		$10.6M Buy
+260,934
New +$11.1M 0.06% 326

Other funds holding BSX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Calamos Advisors's BSX Position: Q3 2026 in Review

Calamos Advisors reduced its Boston Scientific (BSX) stake by 18% in Q3 2026, selling an estimated $5.52M and leaving 557,978 shares worth $24.4M. The position accounts for 0.07% of the portfolio, ranked #249.

Calamos Advisors first reported a position in BSX in Q3 2019 and has held it in 29 quarters since. The position peaked at $107M in Q2 2025. 1,274 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • Calamos Advisors held 557,978 shares of Boston Scientific worth $24.4M as of Q3 2026.
  • Calamos Advisors sold 119,136 Boston Scientific shares in Q3 2026, an estimated $5.52M.
  • Boston Scientific made up 0.07% of Calamos Advisors's portfolio in Q3 2026, its #249 holding.
  • Calamos Advisors first reported a position in Boston Scientific in Q3 2019 and has held it in 29 quarters since.
  • Calamos Advisors's Boston Scientific position peaked at $107M in Q2 2025.
  • 1,274 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Calamos Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.